Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
HYDERABAD, India, July 5th, 2007 – Several data
presentations from Suven’s portfolio of investigational
neuroscience compounds will be presented at
International Brain Research Organisation (IBRO) 2007 World
Congress of Neuroscience to be held at Melbourne, Australia during
July 12-17, 2007.
Scientists from Suven Discovery Research will be presenting new
data for 4 promising areas of neuroscience viz. Alzheimer’s,
Schizophrenia, Parkinson and Obesity diseases. These areas present
significant unmet medical need for which current treatment options
are insufficient. Suven has a number of programs in each of these
areas, focusing on novel approaches that may lead to the
development of new therapies for patients.
Suven is presenting the data on their leading preclinical
candidates SUVN-502 and SUVN-507 at IBRO 2007 world congress of
Neuroscience .
Suven is committed to neuroscience research and for development of
new treatments for neurological disorders. Suven’s discovery
research focuses on Central Nervous System (CNS) disorders
through novel mechanisms using small-molecule medicinal chemistry
approaches. Suven’s CNS drug discovery scientists at
Hyderabad, India are pursuing innovative ways to develop treatments
for a variety of CNS disorders like Alzheimer's, Schizophrenia,
Depression, Cognitive disorders and Neurodegeneration.
Suven Life Sciences, a Hyderabad based Life Sciences Company, pioneer in Contract Research And Manufacturing Services (CRAMS) since 1995 in its endeavor to become collaborative research partner (CRP) for global life science companies has embarked on new business model “Drug Discovery and Development Support Services” (DDDSS) with the onset of Intellectual Property Regime in India since January 2005.
A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven’s commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas. Suven has R&D strength of more than 190 professionals with the state of the art infrastructure for Drug Discovery and development activities with 30 clinical research professionals and the front-end project management services from New Jersey, USA. For more information on Suven, please visit our Web site at http://www.suven.com
Risk Statement:
Except for historical information, all of the statements,
expectations and assumptions, including expectations and
assumptions, contained in this news release may be forward-looking
statements that involve a number of risks and uncertainties.
Although Suven attempts to be accurate in making these
forward-looking statements, it is possible that future
circumstances might differ from the assumptions on which such
statements are based. Other important factors which could cause
results to differ materially including outsourcing trends, economic
conditions, dependence on collaborative partnership programs,
retention of key personnel, technological advances and continued
success in growth of sales that may make our products/services
offerings less competitive.
Serene Chambers, Road No.5, Avenue 7, Banjara Hills Hyderabad 500034, India
Tel: 91-40-2354 1142 Fax: 91-40-2354 1152 Email: info@suven.com
